New hope for prostate cancer patients: experimental drug combo enters clinical testing

NCT ID NCT07190300

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a new drug called tulmimetostat to standard prostate cancer treatments can better control the disease in men whose cancer has spread. The first part determines safe doses, and the second part compares the new combination against standard treatment alone. Researchers aim to see if this approach can slow cancer growth and improve patient outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

Wollongong, New South Wales, 2500, Australia
Novartis Investigative Site
RECRUITING

Guangzhou, 510060, China
Novartis Investigative Site
RECRUITING

Créteil, 94010, France
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Hong Kong, 999077, Hong Kong
Novartis Investigative Site
RECRUITING

Budapest, H-1083, Hungary
Novartis Investigative Site
RECRUITING

Szeged, 6725, Hungary
Novartis Investigative Site
RECRUITING

Seoul, 05505, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
RECRUITING

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Wichita Urology Group PA
RECRUITING

Wichita, Kansas, 67226, United States

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)